04/17/2015
Federal Register Notice: FDA has determined the regulatory review period for Hyperion Therapeutics’ Ravicti is 2,126 days fo...04/06/2015
Federal Register Notice: FDA’s proposed collection of information, “Comparative Price Information in Direct-to-Consume...04/06/2015
Federal Register Notice: FDA’s proposed collection of information, “Survey of Health Care Practitioners for Device Lab...04/06/2015
Federal Register Notice: FDA’s Blood Products Advisory Committee will meet 5/13, from 8 a.m. to 5:30 p.m. at the FDA White O...04/06/2015
Federal Register Notice: FDA will co-sponsor an educational conference with the Society of Clinical Research Associates 5/13-14 fr...04/06/2015
Federal Register Notice: FDA has determined the regulatory review period for Aegerion Pharmaceuticals’ Juxtapid (lomitapide ...04/06/2015
Federal Register Final rule: FDA is amending the standing advisory committees’ regulations to change the name of the Anti-In...04/06/2015
Federal Register Final order: FDA is classifying the urethral insert with pump for bladder drainage into Class 2 (special controls...